Voyager Therapeutics (Nasdaq: VYGR) to Ring The Nasdaq Stock Market Opening Bell

ADVISORY, April 25, 2016 (GLOBE NEWSWIRE) --

Voyager Therapeutics (Nasdaq:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), will visit the Nasdaq MarketSite in Times Square ahead of the company’s R&D Day on Friday, April 29, 2016.

In honor of the occasion, Steven Paul M.D., President and Chief Executive Officer, will ring the Opening Bell.

Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

Tuesday, April 26, 2016 – 9:15 a.m. to 9:30 a.m. ET

Voyager Therapeutics Media Contact:
Katie Engleman
(910) 509-3977

Nasdaq MarketSite:
Emily Pan
(646) 441-5120

Feed Information:
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page:

For photos from ceremonies and events visit our Instagram page:

For livestream of ceremonies and events visit our YouTube page:

For news tweets, please visit our Twitter page:

For exciting viral content and ceremony photos visit our Tumblr page:

A live stream of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.

About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system. Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company’s pipeline is focused on severe CNS diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease and spinal muscular atrophy (SMA). Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com. Follow Voyager on LinkedIn.

About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of approximately $9.3 trillion and nearly 17,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.


Source:NASDAQ, Inc.